Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Antipsychotics in China
I'm PortAI, I can summarize articles.
Luye Pharma Group Ltd. has granted Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd. exclusive rights to commercialize three long-acting injectable antipsychotics in China. The agreement includes a ten-year term and a one-time, non-refundable licensing fee of USD 20 million. Luye Pharma retains product ownership, marketing authorizations, and intellectual property rights, and will handle manufacturing and supply.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments